en · de · es · pt
cardarine-notes.peptides6823.com › Info › Regulatory Status And Detection Context — Reference Sheet

Regulatory Status And Detection Context — Reference Sheet

By Editorial Desk · published 2026-07-07 · last reviewed 2026-07-21 · Info

A practical reference on Anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.

Regulatory Status and Detection Context

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine at a glance

PropertyValueNotes
Regulatory statusNot approved for human therapeutic useNo marketing authorization identified in major jurisdictions.
Anti-doping classPPARδ agonist; hormone and metabolic modulatorsListed on the WADA Prohibited List.
Common test matrixUrineAlso blood and tissue in research settings.
Typical analytical methodLC-MS/MSTargets parent compound and metabolites.
Major safety signalTumor findings in rodentsHuman relevance not established; limited human data.

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Related pages on this site

Mechanism and Detection

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Background and Regulatory History

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

Notes from published material

==== Proposed joint US-USSR program ==== After a first US-USSR Dryden-Blagonravov agreement and cooperation on the Echo II balloon satellite in 1962, President Kennedy proposed on September 20, 1963, in a speech before the United Nations General Assembly, that the United States and the Soviet Union join forces in an effort to reach the Moon. Kennedy thus changed his mind regarding the desirability of the space race, preferring instead to ease tensions with the Soviet Union by cooperating on projects such as a joint lunar landing. Soviet Premier Nikita Khrushchev initially rejected Kennedy's proposal. However, on October 2, 1997, it was reported that Khrushchev's son Sergei claimed Khrushchev was poised to accept Kennedy's proposal at the time of Kennedy's assassination on November 22, 1963. During the next few weeks he reportedly concluded that both nations might realize cost benefits and technological gains from a joint venture, and decided to accept Kennedy's offer based on a measure of rapport during their years as leaders of the world's two superpowers, but changed his mind and dropped the idea since he lacked the same trust for Kennedy's successor, Lyndon Johnson. Some cooperation in robotic space exploration nevertheless did take place, such as a combined Venera 4–Mariner 5 data analysis under a joint Soviet–American working group of COSPAR in 1969, allowing a more complete drawing of the profile of the atmosphere of Venus. Eventually the Apollo–Soyuz mission was realized afterall, which furthermore laid the foundations for the Shuttle-Mir program and the ISS.

The alkali metals form many intermetallic compounds with each other and the elements from groups 2 to 13 in the periodic table of varying stoichiometries, such as the sodium amalgams with mercury, including Na5Hg8 and Na3Hg. Some of these have ionic characteristics: taking the alloys with gold, the most electronegative of metals, as an example, NaAu and KAu are metallic, but RbAu and CsAu are semiconductors. NaK is an alloy of sodium and potassium that is very useful because it is liquid at room temperature, although precautions must be taken due to its extreme reactivity towards water and air. The eutectic mixture melts at −12.6 °C. An alloy of 41% caesium, 47% sodium, and 12% potassium has the lowest known melting point of any metal or alloy, −78 °C.

Between 1922 and 1934 Oscar Tiegs was almost entirely concerned with the physiology of nerve and muscle, apparently influenced by Brailsford Robertson. In 1925 he published the results of experiments regarding the importance of creatine. This line of research was inspired by the lactic acid hypotheses of muscular action at the time and before phosphagen was discovered.

== Outlook == The long-term course of MCTD may vary. Long-term follow-up studies have shown that MCTD can progress to a moderate disease with a favorable prognosis, or patients can acquire a significant condition with vascular alterations driven by pulmonary hypertension and increased mortality. Approximately one-third of people with MCTD have a benign course and go into remission, while the other one-third have a more aggressive course with a poor response to treatment. Approximately one-third of MCTD patients improved with immunosuppressive medication but continued to require immunosuppressive therapy after several years. The prevalence of pulmonary hypertension was related to the worst prognosis and a high mortality rate, making it the most significant complication in MCTD.

Sources: en.wikipedia.org

Further detail

== Criticism == Early skepticism toward lobotomy emerged in Soviet psychiatry. As reports on leucotomy and lobotomy surfaced in Soviet medical journals between 1936 and 1937, followed by more extensive reviews of Freeman and Watts's initial studies in 1939, Soviet reviewers expressed alarm at the procedure's severe complications and a reported 5 percent mortality rate, while also questioning its efficacy, observing that symptoms like fear, depression, and agitation often resolved spontaneously without necessitating such a dramatic procedure. These reviews suggested lobotomy should not be performed in the USSR. Later, by 1944, an author in the Journal of Nervous and Mental Disease remarked: "The history of prefrontal lobotomy has been brief and stormy. Its course has been dotted with both violent opposition and with slavish, unquestioning acceptance." Beginning in 1947 Swedish psychiatrist Snorre Wohlfahrt evaluated early trials, reporting that it is "distinctly hazardous to leucotomize schizophrenics" and that lobotomy was "still too imperfect to enable us, with its aid, to venture on a general offensive against chronic cases of mental disorder", stating further that "Psychosurgery has as yet failed to discover its precise indications and contraindications and the methods must unfortunately still be regarded as rather crude and hazardous in many respects." In 1948 Norbert Wiener, the author of Cybernetics: Or the Control and Communication in the Animal and the Machine, said: "Prefrontal lobotomy...

The prostate is an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. It is found in all male mammals. It differs between species anatomically, chemically, and physiologically. Anatomically, the prostate is found below the bladder, with the urethra passing through it. It is described in gross anatomy as consisting of lobes and in microanatomy by zone. It is surrounded by an elastic, fibromuscular capsule and contains glandular and connective tissue. The prostate produces and contains fluid that forms part of semen, the substance emitted during ejaculation as part of the male sexual response. This prostatic fluid is slightly alkaline, and milky or white in appearance. The alkalinity of semen helps neutralize the acidity of the vaginal tract, prolonging the lifespan of sperm. The prostatic fluid is expelled in the first part of ejaculate, together with most of the sperm, because of the action of smooth muscle tissue within the prostate. In comparison with the few spermatozoa expelled together with mainly seminal vesicular fluid, those in prostatic fluid have better motility, longer survival, and better protection of genetic material. Disorders of the prostate include enlargement, inflammation, infection, and cancer. The word prostate is derived from Ancient Greek prostátēs (προστάτης), meaning "one who stands before", "protector", "guardian", with the term originally used to describe the seminal vesicles.

The rhizomes of lotus (Chinese: 蓮藕; pinyin: lián'ǒu, Japanese: 蓮根, romanized: renkon, Kashmiri: Nadurᵘ, Korean: 연근; Hanja: 蓮根; RR: yeongeun, Hindi: कमल ककड़ी, romanized: kamala kakaṛī, Sindhi Beeh, Telugu: అల్లిదుంప, romanized: alli'dumpa) are consumed as a vegetable in Asian countries, extensively in China, Japan, India, Pakistan (Sindh). They are sold whole or in cut pieces, fresh, frozen, or canned. They can be fried, cooked in soups, soaked in syrup, or pickled in vinegar (with sugar, chili and garlic). Lotus rhizomes have a crunchy texture and are a classic dish at many banquets, where they are deep-fried, stir-fried, or stuffed with meats or preserved fruits. Salads with prawns, sesame oil or coriander leaves are also popular. Fresh lotus root slices brown quickly. Lotus root tea is consumed in Korea. Lotus root is a popular vegetable in Sri Lanka, where it is often cooked in coconut milk gravy. In India, lotus root (also known as kamala kakaṛī in Hindi) is cooked as a dry curry or sabzî. Japan is one of the primary users of the rhizomes, where it represents about 1% of all vegetables consumed. Japan grows its own lotus but still must import 18,000 tons of lotus rhizome each year, of which China provides 15,000 tons yearly. The rhizomes of Nelumbo nucifera contain high amounts of starch (31.2%) without a characteristic taste or odor. The texture is comparable to a raw potato.

Sources: en.wikipedia.org

Supporting material

== Use of methadone clinics internationally == Methadone clinics can provide methadone for on-site administration. Additionally, some methadone clinics provide the following: oversight of treatment, observed dosing, consultation services, urine drug test, naloxone distribution, mental health services, primary care services, and HIV and HCV services.

The compound is now under active investigation by researchers at NIMH for potential clinical use, and it is hoped that use of HNK instead will mitigate the various concerns (such as abuse and dissociation) of using ketamine itself in the treatment of depression.

=== Metabolome atlas of the aging mouse brain === In 2021, the first brain metabolome atlas of the mouse brain – and of an animal (a mammal) across different life stages – was released online. The data differentiates by brain regions and the metabolic changes could be "mapped to existing gene and protein brain atlases".

==== Abhidharma interpretations ==== Prayudh Payutto notes that in Buddhaghosa's Sammohavinodani, a commentary to the Vibhaṅga, the principle of dependent origination is explained as occurring entirely within the space of one mind moment. Furthermore, according to Payutto, there is material in the Vibhaṅga which discusses both models, the three lifetimes model (at Vibh.147) and the one mind moment model. Similarly, Cox notes that the Sarvastivadin Vijñānakāya contains two interpretations of dependent origination, one which explains the 12 nidanas as functioning in a single moment as a way to account for ordinary experience and another interpretation that understands the 12 nidanas as arising sequentially, emphasizing their role in the functioning of rebirth and karma. Wayman notes that an interpretation referring to mental processes (referred to as dependent origination with a transient character) can also be found in northern sources, such as the Jñānaprasthāna, the Arthaviniscaya-tika and the Abhidharmakosa (AKB.III.24d). The Jñānaprasthāna, explains the nidanas with the example of the act of killing. Ignorance leads to the motivation to kill, which is acted on through consciousness, name and form and so on. This leads to mental karma being generated (bhava) which leads to the movement of the hand to kill (birth). The different interpretations of dependent origination as understood in the northern tradition can be found in the Abhidharmakosa, which outlines three models of the twelve nidanas:

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Why is cardarine prohibited in sport?

It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.

What is known about cardarine and cancer?

Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Network